BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company specializing in treatments for neuroinflammatory diseases, has announced a proposed public offering of common stock. The company is aiming to raise $125 million through this offering, with an option for underwriters to purchase an additional $18.750 million of shares. The completion of the offering is subject to various conditions, including market factors and investor interest. J.P. Morgan, Jefferies, TD Cowen, BofA Securities, and Wells Fargo Securities are serving as joint book-running managers for the offering.
Annexon’s focus on developing innovative therapies for classical complement-mediated neuroinflammatory diseases sets it apart in the biopharmaceutical industry. This proposed public offering highlights the company’s commitment to advancing its novel scientific approach to benefit individuals affected by a range of autoimmune, neurodegenerative, and ophthalmic conditions. The move to raise additional funds underscores Annexon’s dedication to accelerating the development and availability of potential treatments for patients in need.
